Aeglea BioTherapeutics Investor Presentation Deck

SPY001 Phase 1 clinical trial design. ● SINGLE-ASCENDING DOSE SAD 1 SC SAD 2 SC SPYRE SAD 3 SC Single-ascending dose cohorts Healthy volunteers N=8/cohort (3:1 randomization) Expected interim YE2024 readout to include 2-3 SAD cohorts and is sufficient to answer key objectives with PK modeling SAD 4 IV I I I I I ● MULTIPLE-ASCENDING DOSE ● MAD 1 SC Multiple-ascending dose cohorts Healthy volunteers N=8/cohort (3:1 randomization) Two doses MAD 2 SC 12

View entire presentation